RAN-MONTELUKAST TABLET (CHEWABLE)
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
21-03-2016
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
MONTELUKAST (MONTELUKAST SODIUM)
Inapatikana kutoka:
RANBAXY PHARMACEUTICALS CANADA INC.
ATC kanuni:
R03DC03
INN (Jina la Kimataifa):
MONTELUKAST
Kipimo:
5MG
Dawa fomu:
TABLET (CHEWABLE)
Tungo:
MONTELUKAST (MONTELUKAST SODIUM) 5MG
Njia ya uendeshaji:
ORAL
Vitengo katika mfuko:
30
Dawa ya aina:
Prescription
Eneo la matibabu:
LEUKOTRIENE MODIFIERS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0133823001; AHFS:
Idhini hali ya:
CANCELLED POST MARKET
Idhini ya tarehe:
2022-07-28
Tabia za bidhaa
1
`
PRODUCT MONOGRAPH
PR
RAN™-MONTELUKAST
Montelukast Chewable Tablets
montelukast (as montelukast sodium)
4mg and 5mg
Leukotriene Receptor Antagonist
Ranbaxy Pharmaceuticals Canada Inc.
DATE OF REVISION:
126 East Drive
March 21, 2016
Brampton, ON
L6T 1C1
Control #: 192448
RAN Trademark owned by Sun Pharmaceutical Industries Ltd.
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
3
SUMMARY PRODUCT INFORMATION
..........................................................................................
3
INDICATIONS AND CLINICAL USE
................................................................................................
3
CONTRAINDICATIONS
.....................................................................................................................
4
WARNINGS AND PRECAUTIONS
....................................................................................................
4
ADVERSE REACTIONS
.....................................................................................................................
7
DRUG INTERACTIONS
....................................................................................................................
10
DOSAGE AND ADMINISTRATION
................................................................................................
12
OVERDOSAGE
..................................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
..............................................................................
13
STORAGE AND STABILITY
............................................................................................................
16
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................................... 17
PART II: SCIENTIFIC INFORMATION
...........................................................................................
18
CLINICAL TRIALS
....................
Soma hati kamili
